Avecho Biotechnology (ASX:AVE) said that three newly activated sites in Sydney and the Gold Coast have started screening and recruitment for its phase three clinical trial investigating its oral cannabidiol capsule for the treatment of insomnia, according to a Tuesday filing with the Australian bourse.
The sites provide access to independent databases of insomnia patients, the filing said.
The trial will dose about 210 participants before the end of the year, with results expected in early 2026, the filing added.
Shares of the company rose 11% at market close.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。